pd-0325901 has been researched along with Triple-Negative-Breast-Neoplasms* in 1 studies
1 other study(ies) available for pd-0325901 and Triple-Negative-Breast-Neoplasms
| Article | Year |
|---|---|
[Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
MEK inhibition activates PI3K/AKT/mTOR pathway in triple negative breast cancer (TNBC) cell lines. Combination of PI3K inhibitor and MEK1/2 inhibitor is not appropriate for PI3K inhibitor insensitive TNBC cell lines. This study was designed to investigate the effects of dual treatments with mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901 in MDA-MB-435 cell line. MEK1/2 inhibition led to activation of AKT, which is the downstream signaling protein of PI3K pathway. The combination inhibited the phosphorylation of AKT and therefore abolished the feedback interaction of two pathways. Cell proliferation assay and DNA replication assay demonstrated that the dual treatments led to a significant synergistic inhibition of cell cycle progression and cell proliferation. Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2016 |